Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Mónica Galli et al.|The Lancet Oncology|2019Cited by 386
Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myelomaС. В. Семочкин, Л. П. Менделеева, M. V. Solovyev|Oncohematology|2022Cited by 6